Monte Rosa Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
Monte Rosa Therapeutics, a biotechnology firm (NASDAQ: GLUE), will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from Nov. 30 to Dec. 2, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Monte Rosa Therapeutics, a biotechnology firm (NASDAQ: GLUE), will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from Nov. 30 to Dec. 2, 2021. The management team's pre-recorded fireside chat is accessible for registered attendees via the conference site from Nov. 22 to Dec. 2. Additionally, an archived version of the chat will be available on the company’s investor site in the “Events & Presentations” section. Monte Rosa is focused on developing molecular glue degrader medicines through its proprietary QuEEN™ platform, leveraging advanced technologies for protein degradation.
Details
News Market Reaction – GLUE
The recorded move for GLUE in the trading session of this news was +0.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced members of its management team will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference from Nov. 30-Dec. 2, 2021. The company’s pre-recorded fireside chat is available for registered attendees via the Piper Sandler conference site from Nov. 22-Dec. 2.
An archived webcast of the fireside chat can be accessed via the “Events & Presentations” section of the company’s investor site at https://ir.monterosatx.com/.
About Monte Rosa
Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader medicines. These medicines are designed to employ the body’s natural mechanisms to selectively eliminate therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates), that enables it to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, AI/machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. For more information, visit www.monterosatx.com.
Contacts:
Investors
Michael Morabito, Solebury Trout
ir@monterosatx.com
Media
Dan Budwick, 1AB
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.